Ocular Therapeutix reports Q3 2026 loss and revenue miss

Ocular Therapeutix posted third‑quarter 2026 GAAP loss of $0.42 per share on net loss of $94.8 million. Revenue fell 11.5% year‑over‑year to $12.87 million, missing consensus estimates by about $1.0 million. Selling and marketing expenses rose to $15.7 million and R&D to $74.8 million, while cash and cash equivalents stood at $530.6 million. The stock dropped 7.4% after the release.

The earnings miss and widening loss drove the share price down 7.4%. The sizable cash balance of $530.6 million should fund operations into 2028, limiting immediate financing risk.

Sources